Dana Narvaez, Oncologist at Alexander Fleming Institute, Global Oncology Subcommittee (Community of Practice – Health Policy) at American Society of Clinical Oncology, shared a post on LinkedIn about a recent article she and her colleague co-authored, adding:
“Our editorial comment on the clinical utility and current challenges of ctDNA surveillance in breast cancer is out in Therapeutic Advances in Medical Oncology.
ctDNA is one of the most promising tools in breast oncology for detecting MRD enabling personalized treatment.”
Title: Comment on: Exploring the utility of ctDNA testing in high-risk breast cancer patients in a community setting: case series
Authors: Dana Narvaez, Federico Waisberg
Read the Full Article on Therapeutic Advances in Medical Oncology
More posts featuring Breast Cancer.